Synnovation Therapeutics is a technology company.
Synnovation Therapeutics has raised $100.0M across 1 funding round.
Synnovation Therapeutics has raised $100.0M in total across 1 funding round.
Synnovation Therapeutics has raised $100.0M in total across 1 funding round.
Synnovation Therapeutics's investors include Johnson & Johnson Innovation, Sofinnova Investments, Third Rock Ventures.
Synnovation Therapeutics is a precision oncology company developing small molecule therapies that target key driver mechanisms in cancers to advance patient-focused precision medicine.[1][2][3] Founded in 2021 in Wilmington, Delaware, it leverages expertise in cancer biology and medicinal chemistry to build a diverse pipeline of best-in-class and first-in-class therapeutics, aiming to efficiently move them into clinical trials and transform cancer care.[1][2][3] The company serves cancer patients by addressing unmet needs through innovative targeted treatments, with strong growth momentum including a Series A funding round of $102M (total funding $139M as of December 2023) and plans to expand its workforce from around 30 to over 70 by 2026, creating 44 high-paying jobs in Delaware.[3][4]
Synnovation Therapeutics was founded in 2021 in Wilmington, Delaware, by Wenqing Yao, a founding scientist from Incyte, drawing on deep experience in oncology drug development.[3][4] Key early leaders include Executive Director Hui Wang, who previously served as associate director of small molecule therapy oncology programs at Incyte, highlighting the team's roots in established pharma innovation.[5] The idea emerged from expertise in cancer biology and medicinal chemistry, leading to rapid early traction: since launch, the company has advanced its portfolio of targeted oncology molecules and secured significant Series A funding led by investors like Cormorant Asset Management, Lilly Asia Ventures, Third Rock Ventures, Nextech Invest, and Sirona Capital in December 2023.[3][4] Operating from The Innovation Space near Wilmington, this Delaware-founded biotech has steadily grown its team while positioning itself as a leader in precision medicine.[3]
Synnovation rides the precision medicine trend in oncology, where targeted small molecule therapies outperform traditional treatments by focusing on specific cancer drivers, amid rising demand for personalized cancer care.[1][2][3] Timing is ideal post-2021 founding, capitalizing on post-pandemic biotech investment surges and regional strengths in pharma innovation like Incyte's legacy in Delaware.[3][5] Market forces favoring it include U.S. life sciences growth, with Delaware's ecosystem supporting expansion, and broader tailwinds in oncology R&D driven by aging populations and unmet needs in hard-to-treat cancers.[3][4] By advancing its pipeline, Synnovation influences the ecosystem as a job creator and innovator, bolstering the Delaware-Philadelphia region's status as a precision medicine center.[3]
Synnovation is poised to advance its pipeline into clinical trials, potentially yielding breakthroughs in targeted oncology therapies amid accelerating precision medicine adoption.[1][2][3] Trends like AI-enhanced drug discovery and combination therapies will shape its path, with workforce doubling by 2026 signaling aggressive scaling.[3][4] Its influence may evolve from early-stage innovator to clinical leader, further solidifying Delaware's biotech prominence—transforming science into life-improving cancer treatments as promised.[1][3]
Synnovation Therapeutics has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $100.0M Series A | Johnson & Johnson Innovation, Sofinnova Investments, Third Rock Ventures |